Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.80 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.69 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.69 |
| ▸ | FBP1 | P09467 | 1/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.63 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.63 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.63 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.63 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.63 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9948576 | 0.94 | HDAC3 (0.73) | EGFRERBB2ERBB4HDAC3HDAC4 | |
| SCHEMBL21620272 | 0.92 | EGFR (0.68) | EGFRERBB2ERBB4FBP1HDAC3 | |
| SCHEMBL1417948 | 0.92 | EGFR (0.67) | EGFRERBB2ERBB4HDAC3HDAC4 | |
| SCHEMBL13973714 | 0.91 | EGFR (0.65) | EGFRERBB2ERBB4FBP1HDAC3 | |
| SCHEMBL10080590 | 0.91 | EGFR (0.65) | EGFRERBB2ERBB4FBP1HDAC3 | |
| SCHEMBL5375309 | 0.89 | EGFR (0.64) | EGFRERBB2ERBB4HDAC3HDAC4 | |
| SCHEMBL15932944 | 0.89 | EGFR (0.67) | EGFRERBB2ERBB4HDAC3HDAC4 | |
| SCHEMBL25859436 | 0.89 | EGFR (0.90) | EGFRERBB2ERBB4FBP1HDAC3 | |
| SCHEMBL16693868 | 0.87 | EGFR (0.67) | EGFRERBB2ERBB4FBP1HDAC3 | |
| SCHEMBL18660066 | 0.87 | EGFR (0.86) | EGFRERBB2ERBB4FBP1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2479174-B1 | 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2017-10-18 | — | — | EP | disclosed |
| EP-2479174-B1 | 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2017-10-18 | — | — | EP | disclosed |
| US-9358227-B2 | Pharmaceutical uses of 6-amino quinazoline or 3-cyano quinoline derivatives | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2016-06-07 | — | — | US | disclosed |
| US-9358227-B2 | Pharmaceutical uses of 6-amino quinazoline or 3-cyano quinoline derivatives | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2016-06-07 | — | — | US | disclosed |
| US-20150126550-A1 | PHARMACEUTICAL USES OF 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2015-05-07 | — | — | US | disclosed |
| US-20150126550-A1 | PHARMACEUTICAL USES OF 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2015-05-07 | — | — | US | disclosed |
| US-8901140-B2 | 6-amino quinazoline or 3-cyano quinoline derivatives, preparation methods and pharmaceutical uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2014-12-02 | — | — | US | disclosed |
| US-8901140-B2 | 6-amino quinazoline or 3-cyano quinoline derivatives, preparation methods and pharmaceutical uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2014-12-02 | — | — | US | disclosed |
| EP-2479174-A1 | 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2012-07-25 | — | — | EP | disclosed |
| EP-2479174-A1 | 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2012-07-25 | — | — | EP | disclosed |
| US-20120165352-A1 | 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-06-28 | — | — | US | disclosed |
| US-20120165352-A1 | 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165352-A1 | 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | CSNK1G3, CSNK1A1, CSNK1A1L | EGFR 3299/4885ERBB2 851/4885ERBB4 1117/4885 |
| US-20150126550-A1 | PHARMACEUTICAL USES OF 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES | PYGL, CSNK1G3, G6PD | EGFR 2980/4885ERBB2 901/4885ERBB4 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.